Injectable GHK-Cu delivers copper directly into tissue, potentially contributing to total body copper load
Food and Drug Administration for any indication, off-label use among researchers and in experimental settings has grown, driven primarily by animal studies and anecdotal reports
Results clearly showed that the activation index was rescued up to a level comparable to a positive control culture ( bar 2 ) exposed to untreated HGF at the 5 ng/ml dose that maximizes satellite cell activation in our culture platform ( bars 7 and 11 ) 19
For chronic GI conditions including irritable bowel syndrome, inflammatory bowel disease, gastritis, and peptic ulcers, the peptide may offer unique benefits
This situation contrasts sharply with approved peptide drugs, which must meet rigorous quality standards
Another study with CuCl 2 treated Hep G2 cell line demonstrated that mitochondrial toxicity is an intermediate-level event associated with copper toxicity to Hep G2 cells while lysosomal damage is the early event and plasma damage a late feature associated with copper toxicity 34